LOGIN  |  REGISTER
Chimerix
Cue Biopharma

Sonida Senior Living Announces Participation in Upcoming Conferences

May 08, 2025 | Last Trade: US$26.05 0.11 -0.42

DALLAS / May 08, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in the following upcoming investor conferences:

  • 2025 BMO North American Real Estate Conference (New York City) Sonida management will participate in one-on-one meetings with institutional investors on May 13th and 14th.
  • 2025 RBC Capital Markets Global Healthcare Conference (New York City) Sonida management will participate in one-on-one meetings on May 20th and 21st. Brandon Ribar will participate in a fireside chat moderated by Ben Hendrix, RBC Research, on May 21st at 11:30 a.m. ET. A webcast of the chat will be available on the Company’s investor relations website in the Events and Presentations section following the event.

To schedule a one-on-one meeting, please contact your bank representative.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including four owned through joint venture investments in consolidated entities, four owned through a joint venture investment in an unconsolidated entity, and one unoccupied), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page